Medpace
MEDP | NASDAQ
$648.20
-$5.74 (-0.88%)
At close: Nov 16, 2026, 4:00 PM ET
$648.20
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Medpace Company Profile
Company profile explainedCompany Profile
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Key Executives
| Name | Position |
|---|---|
| August James Troendle | CEO, President & Chairman |
| Kevin Brady | Chief Financial Officer & Treasurer |
| Brad W. Hansman | Executive Vice President of Operations |
| Gina Leisring | Senior Vice President of Clinical Monitoring |
| John T. Wynne | Chief Business Officer |
| Lauren Morris | Associate Director of Investors Relations |
| Reinilde Heyrman | Chief Medical Officer of Medical Department |
| Stephen Ewald | Chief Compliance Officer, General Counsel & Corporate Secretary |
| Todd Meyers | Vice President of Business Development & Marketing |
| Weimin Gai | Senior Vice President of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 4 | Filing |
| Oct 23, 2026 | 4 | Filing |
| Oct 22, 2026 | 10-Q | Quarterly Report |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 4 | Filing |
| Oct 09, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 01, 2026 | 4 | Filing |
Medpace
| Country | United States |
| IPO Date | Aug 11, 2016 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 6,600 |
| CEO | August James Troendle |
Contact Details
5375 Medpace Way Cincinnati,
Ohio 45227 United States
Stock Details
| Ticker Symbol | MEDP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668397 |
| CUSIP Number | 58506Q109 |
| ISIN Number | US58506Q1094 |
| SIC Code | 8731 |
Recent News
- 3 days ago / zacks.comIs Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
- 5 days ago / zacks.com3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
- 18 days ago / zacks.comMedpace (MEDP) is a Great Momentum Stock: Should You Buy?
- 19 days ago / zacks.comMedpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
- 22 days ago / zacks.comIs Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
- 22 days ago / zacks.comAll You Need to Know About Medpace (MEDP) Rating Upgrade to Buy
- 22 days ago / zacks.comHere's Why Medpace (MEDP) is a Strong Growth Stock
- 23 days ago / seekingalpha.comMedpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
- 25 days ago / fool.comMedpace: 3 Key Takeaways for Long-Term Investors
- 26 days ago / seekingalpha.comMedpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove MEDP